e-ISSN 2147-2475

Hzl Arama




nvazif rotelyal Karsinomlu Hastada Paklitaksele Bal Akcier Toksisitesi [Respir Case Rep]
Respir Case Rep. 2018; 7(3): 154-157 | DOI: 10.5505/respircase.2018.15013

nvazif rotelyal Karsinomlu Hastada Paklitaksele Bal Akcier Toksisitesi

Merve Erelik1, zlem Ataolu1, Pnar Yldz Glhan1, Fuat Aytekin1, Mehmet Fatih Elverili1, Onur Ebah2, Ege Gle Balbay1
1Dzce niversitesi, Gs Hastalklar Ana Bilim Dal, Dzce
2Dzce niversitesi, Onkoloji Bilim Dal, Dzce

Paklitaksel, mikrotbl hiperstabilizasyon yoluyla mitotik duraklamay balatan bir anti-kanser ilac olup hidrofobiklii ve hcresel seicilii olmamas nedeniyle yan etkilere neden olmaktadr. Yetmi bir yanda erkek hasta gs hastalklar polikliniine 2 haftadr olan nefes darl ikyeti ile bavurdu. Kasm 2016 da mesane kaynakl invazif rotelyal mesane karsinom tans alan hasta 2 kr Paklitaksel tedavisi almt. Hastann posteroanterior akcier grafisinde bilateral periferik infiltrasyonlar mevcuttu. Yksek Rezolsyonlu Bilgisayarl Tomografide her iki akcierde sada daha belirgin olmak zere periferal-subplevral interlobler septal kalnlamalar, retikler dansiteler, buzlu cam younluk alanlar, periferal yamasal fokal konsolide alanlar izlendi. zellikle her iki alt lob posterobazal segmentlerde periferal yerleimli traksiyon bronektaziler izlendi. Bron lavajnda; hiperplastik rezerv hcreler, makrofajlar, bakteri kmeleri, PNL izlendi, atipik hcre gzlenmedi. Hastada mevcut bulgularla Paklitaksel toksisitesi dnld, kemoterapisi sonlandrld ve metilprednizolon tedavisi baland. Metilprednizolon tedavisinin birinci aynda kontrol akcier grafisinde regresyon izlendi. Paklitaksele bal akcier toksisitesisinin nadir grlmesi nedeniyle bu olguyu sunduk.

Anahtar Kelimeler: Metilprednizolon, Nefes darl, Paklitaksel

Paclitaxel Associated Lung Toxicity in a Patient with Invasive Urothelial Carcinoma

Merve Erelik1, zlem Ataolu1, Pnar Yldz Glhan1, Fuat Aytekin1, Mehmet Fatih Elverili1, Onur Ebah2, Ege Gle Balbay1
1Department of Pulmonary Diseases, Dzce University, Dzce, Turkey
2Department of Oncology, Dzce University, Dzce, Turkey

Paclitaxel is an anti-cancer drug that induces mitotic arrest via microtubule hyperstabilization, but which also causes side effects due to its hydrophobicity and cellular promiscuity. A 71-year-old male patient presented at the polyclinic with dyspnea present for 2 weeks. In November 2016, the patient had been diagnosed with bladder-derived invasive urothelial bladder carcinoma and received 2 cycles of paclitaxel therapy. High-resolution computed tomography revealed peripheral-subpleural interlobular septal thickening, reticular densities, ground-glass density areas, and peripheral focal consolidation in both lungs, particularly on the right. Peripheral traction bronchiectasis was also observed, especially in the posterobasal segments of both lower lobes. Bronchial lavage revealed hyperplastic reserve cells, macrophages, bacterial clusters, and polymorphonuclear leukocytes, but no atypical cell were observed. The infection was ruled out. Chemotherapy was terminated and methylprednisolone (0.75 mg/kg) was initiated. Regression was observed in a control posteroanterior chest graphy after 1 month of steroid therapy. This case was presented because lung toxicity due to paclitaxel is rare.

Keywords: Dyspnea, Methylprednisolone, Paclitaxel

Olgunun Tomografi Kesitleri


Tedavi Srei




Merve Erelik, zlem Ataolu, Pnar Yldz Glhan, Fuat Aytekin, Mehmet Fatih Elverili, Onur Ebah, Ege Gle Balbay. Paclitaxel Associated Lung Toxicity in a Patient with Invasive Urothelial Carcinoma. Respir Case Rep. 2018; 7(3): 154-157

Sorumlu Yazar: Merve Erelik, Trkiye
LookUs & Online Makale